AnGesAMGXF 53 PS Ratio is 21.19 as of Jul. 08, 2026, which is 81% below its 10-year median of 109.21. GuruFocus rates AMGXF with a GF Score™ of 53/100 and a GF Value™ of $0.74. The stock has 5 warning signs investors should review. Among 928 Biotechnology companies, AnGes ranks worse than 64.55% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, AnGes's share price is $0.3602.
AnGes's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.02. Hence, AnGes's PS Ratio for today is 21.19.
Good Sign:
AnGes Inc stock PS Ratio (=19.07) is close to 1-year low of 17.28.
The historical rank and industry rank for AnGes's PS Ratio or its related term are showing as below:
AMGXF'
s PS Ratio Range Over the Past 10 Years
Min: 16.51 Med: 109.21 Max: 5684.41
Current: 18.22
During the past 13 years, AnGes's highest PS Ratio was 5684.41. The lowest was 16.51. And the median was 109.21.
AMGXF's PS Ratio is ranked worse than 64.55% of 928
companies
in the Biotechnology industry
Industry Median: 9.59
vs AMGXF: 18.22
AnGes's Revenue per Sharefor the
three
months ended in Dec. 2025 was $0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.02.
Warning Sign:
AnGes Inc revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of AnGes was -9.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 78.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 58.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -18.80% per year.
During the past 13 years, AnGes's highest 3-Year average Revenue per Share Growth Rate was 84.40% per year. The lowest was -60.40% per year. And the median was -19.70% per year.
Back to Basics: PS Ratio
AnGes (OTCPK:AMGXF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
AnGes PS Ratio Related Terms
AnGes PS Ratio Historical Data
* Premium members only.
The historical data trend for AnGes's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, AnGes's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AnGes PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AnGes's PS Ratio distribution charts can be found below:
* The bar in red indicates where AnGes's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
AnGes's Share Price of today is $0.3602. AnGes's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
AnGes (AMGXF) has a PS Ratio of 21.19 as of Jul. 08, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on AnGes and its competitors. This is 81% below median its historical median of 109.21. Over the past decade, AnGes' PS Ratio has ranged from 16.51 to 5,684.41. According to the industry distribution chart, AnGes ranks #599 out of 928 companies in the Biotechnology industry, placing it in the top 64.5%.
Is AnGes' PS Ratio too high?
AnGes' current PS Ratio of 21.19 is 81% below median its 10-year median of 109.21. Over the past 10 years, this metric has ranged from a low of 16.51 to a high of 5,684.41. The Biotechnology industry median PS Ratio is 9.59. AnGes' value of 21.19 is 121% above this industry median. Based on the distribution chart, AnGes ranks #599 out of 928 companies in the Biotechnology industry, which is below the industry midpoint. Overall, AnGes has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does AnGes' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, AnGes ranks #599 out of 928 companies for PS Ratio. This places AnGes in the lower half of its industry. The industry median PS Ratio is 9.59. AnGes' value of 21.19 is 121% above this benchmark. Historically, AnGes' own PS Ratio has ranged from 16.51 to 5,684.41 over the past decade. While the company's 10-year median is 109.21 vs. the industry median of 9.59, AnGes has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.59, based on 928 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AnGes's current PS Ratio of 21.19 is 121% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on AnGes and its competitors. For the Biotechnology industry, the median PS Ratio is 9.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AnGes's current PS Ratio is 21.19, which is 81% below median its own 10-year median of 109.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AnGes stock overvalued right now?
AnGes (AMGXF) has a current PS Ratio of 21.19. The stock's GF Value™ is $0.74, compared to a current price of $0.36 — trading 51.3% below its estimated fair value. The current PS Ratio is 21.19, which is 81% below median its 10-year median of 109.21 and 121% above the Biotechnology industry median of 9.59. AnGes' overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For AnGes (AMGXF), the current PS Ratio is 21.19 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AnGes (AMGXF) Overvalued in 2026?
Based on GuruFocus' analysis, AnGes stock appears to be undervalued.
The current stock price of $0.36 is trading 51.3% below its estimated GF Value™ of $0.74.
Key valuation signals for AMGXF:
PS Ratio: 21.19 (81% below median its 10-year median of 109.21)
GF Value™: $0.74 vs. price of $0.36 (51.3% below fair value)
Industry Position: 121% above the Biotechnology median (#599 of 928)
No single metric tells the full story. See the AMGXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AnGes Inc is a biopharmaceutical company. The company is involved in research and development and sales of pharmaceuticals such as gene-based drugs (gene therapy products, nucleic acid drugs); contract testing for rare genetic diseases, etc.
53GF Score
Get the complete analysis for AMGXF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMGXF has been successfully added to your 
